For the measurement of the growth regulatory hormone N-Acetyl Ser-Asp-Lys-Pro (AcSDKP)
Features
  • Measure AcSDKP in mammalian plasma and urine samples
  • Assay 33 samples in duplicate
  • Incubation: Overnight
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

AcSDKP EIA Kit

Item No. 589451

Kit Booklet (PDF)
Technical Information
Synonyms
  • N-Acetyl Ser-Asp-Lys-Pro ELISA Kit
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Bioanalysis & Assay Development Services
    Your Vision. Our Expertise.
    • Bioanalysis and compound screening using Cayman or qualified commercial assay kits
    • Development and qualification of fit-for-purpose assays in a variety of formats and platforms
    • Experienced scientists dedicated to developing the best strategy for your project
    LEARN MORE
    Product Description

    N-Acetyl Ser-Asp-Lys-Pro (AcSDKP) is a tetrapeptide growth regulatory hormone which inhibits the proliferation of hematopoietic stem cells.1 The dipeptidase Angiotensin Converting Enzyme (ACE) actively metabolizes circulating AcSDKP, giving it a brief plasma half life of 4 to 5 minutes. ACE inhibition is a major therapeutic end point in the treatment of hypertension management. A further consequence of ACE inhibition is the accumulation of AcSDKP in the plasma and the urine.2,3 This accumulation may have physiological effects, which are manifested as the anemia of chronic ACE inhibitor toxicity. More commonly, plasma and urine AcSDKP levels can be used as a biomarker of ACE inhibition and an index of patient compliance with therapy.4 Measurement of AcSDKP in human urine or plasma can be readily accomplished by enzyme immunoassay.5 [Bertin Catalog No. A05881]

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lenfant, M., Wdzieczak-Bakala, J., Guittet, E., et alInhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure. Proc. Natl. Acad. Sci. USA 86, 779-782 (1989).

    2. Azizi, M., Ezan, E., Nicolet, L., et alHigh plasma level of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: A new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30(5), 1015-1019 (1997).

    3. Azizi, M., Ezan, E., Reny, J.L., et alRenal and metabolic clearance of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) during angiotension-converting enzyme inhibition in humans. Hypertension 33(3), 879-886 (1999).

    4. Struthers, A.D., MacFadyen, R., Fraser, C., et alNonadherence with angiotensin-converting enzyme inhibitor therapy. A comparison of different ways of measuring it in patients with chronic heart failure. J. Am. Coll. Cardiol. 34(7), 2072-2077 (1999).

    5. Pradelles, P., Frobert, Y., Créminon, C., et alNegative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem. Biophys. Res. Commun. 170, 986-993 (1990).